United Therapeutics reports first UThymoKidney transplant in EXTEND trial
UTHR•
UTHR•United Therapeutics announced the first UThymoKidney transplant in its EXTEND trial at NYU Langone Health. The study’s first six transplant results will be submitted to the FDA before planned expansion.
United Therapeutics announced the first transplant of a UThymoKidney in its EXTEND trial for patients with end-stage renal disease. The procedure was performed at NYU Langone Health.
EXTEND evaluates a pig kidney containing thymic tissue intended to reduce organ rejection in patients with limited transplant options. It is the second clinical trial in the company’s xenotransplantation program, which aims to support applications for FDA approval. Results from the first six transplants will be submitted to the FDA before planned expansion to additional centers and a larger study population.